Jordi Bove Badell I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases. Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca Jordi Bove Badell Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.
I received a Pharmacy degree from the University of Barcelona in 1998. In 2003, I got a PhD in Pharmacy (Neurobiology) with cum laude distinction from the same university at the Experimental Neurology Laboratory, Neurological Service of Hospital Clínic de Barcelona-IDIBAPS (Dr. C. Marin/Prof. E. Tolosa). My doctoral thesis shed light on the mechanism of levodopa-induced motor fluctuations in Parkinson's disease. I later joined the laboratory of Dr. Serge Przedborski at Columbia University (New York, USA) as a post-doctoral researcher (2003-2005), working on animal modeling and the role of alpha-synuclein in Parkinson's disease. In 2006 I co-founded the Neurodegenerative Diseases Research Group at Vall d’Hebron Research Institute (VHIR) in the Vall d’Hebron Hospital Campus (Barcelona) with its leader Dr. Miquel Vila. In 2011, I obtained a position as a Miguel Servet Investigator (Instituto de Salud Carlos III, Spain) as a Researcher in the National System of Health, and since then I am one of the principal investigators of the group. The research that I am leading is aimed to elucidate the mechanism of neuron cell death and to determine new therapeutic targets to develop neuroprotective strategies for Parkinson’s disease and other neurodegenerative diseases. I am also interested in establishing presymptomatic biomarkers of Parkinson´s disease. I am currently focused on the role of the adaptive immune system in Parkinson’s disease. Our latest published study suggests that a cytotoxic attack induced by CD8 T lymphocytes initiates the disease.
Projects Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación diagnóstica y terapéutica IP: Jordi Bove Badell Collaborators: Oriol de Fabregues-Boixar Nebot Funding agency: Instituto de Salud Carlos III Funding: 134915 Reference: PI15/01937 Duration: 01/01/2016 - 31/12/2018 Apoptosi i Neurodegeneració (GRC) IP: - Collaborators: Marta Martínez Vicente, Miquel Vila Bover, Joaquin Lopez Soriano, Mercè Boada Rovira, Jordi Bove Badell Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 30000 Reference: 2014 SGR 1609 Duration: 01/01/2014 - 31/12/2016 Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment IP: Miquel Vila Bover Collaborators: Jordi Bove Badell, Laia Perez Lasarte Funding agency: Instituto de Salud Carlos III Funding: 202500 Reference: MS11/00229 Duration: 01/01/2012 - 31/12/2016 Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment IP: Jordi Bove Badell Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 121500 Reference: CP11/00229 Duration: 01/01/2012 - 30/06/2015 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page »
